Partner Headlines - AMGN

  1. Drug ETFs Attractive Buys On Pullback

    Benzinga
  2. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD
  3. Daniel Loeb Comments on Amgen Inc

    GuruFocus
  4. Third Point Q3 2014 Investor Letter

    GuruFocus
  5. Markets In Rally Mode: S&P 500 And Nasdaq Surge As Dow Lags

    Benzinga
  6. Third Point's Notable Additions And Exit: Alibaba, eBay, Sony

    Benzinga
  7. Stocks To Watch For October 20, 2014

    Benzinga
  8. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  9. Regeneron's Eylea Tops Rivals

    IBD
  10. Amgen Announces Appointment Of R. Sanders Williams To Board Of ...

    Benzinga
  11. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD
  12. Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

    Benzinga
  13. Most Top Industry Groups Fall Harder Than Market

    IBD
  14. UPDATE: Amgen's BiTE Received FDA Priority Review Designation

    Benzinga
  15. Illumina Pads Gene Sequencing Lead With Pharma Deals

    IBD
  16. Some Old Stocks Still Have Young Legs

    IBD
  17. Amgen, Inc. Showing Strong Performance Despite Low Beta

    Benzinga
  18. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD
  19. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD
  20. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  21. Amgen Submits Biologics License Application For Investigational ...

    Benzinga
  22. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  23. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus
  24. Amgen, Inc. Poised To Break Higher

    Benzinga
  25. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab ...

    Benzinga
  26. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare ...

    Benzinga
  27. Amgen, Inc. Showing More Upside Potential

    Benzinga
  28. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga
  29. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD
  30. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD
  31. Amgen edges up on trial results

    IBD
  32. Stocks Hitting 52-Week Highs

    Benzinga
  33. Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga
  34. After Reaching All-Time Highs, How Can Gilead Sciences Continue ...

    GuruFocus
  35. HCP Boosts Of 29 Years Of Dividend Increases

    IBD
  36. The Tech Industry is Vanishing Before Our Eyes

    FoxBusiness
  37. Stocks End With Small Gains; Amgen Shrugs Off Drug Data

    IBD
  38. AMGEN

    IBD
  39. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  40. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  41. Cancer 'Cocktail' Passes Test

    IBD
  42. Nasdaq Leads In Quiet Session; Priceline Nears Buy Point

    IBD
  43. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  44. Morning Market Movers

    Benzinga
  45. Benzinga's Top #PreMarket Gainers

    Benzinga
  46. UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met ...

    Benzinga
  47. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  48. Amgen Price Target Raised by Various Analysts

    Benzinga
  49. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  50. Quarterly “Beats”: Bah, Here Are Real Growers

    YCharts
  51. Amgen To Slash Workforce

    IBD
  52. Indexes End Lower As Russia Sanctions Hit Stocks

    IBD
  53. Stock Futures Show Some Muscle; Merck, Cognex Rising

    IBD
  54. Earnings Scheduled For July 29, 2014

    Benzinga
  55. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  56. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  57. Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses

    Benzinga
  58. US Stock Futures Drop Ahead Of Durable Goods Orders Data

    Benzinga
  59. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  60. UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 ...

    Benzinga
  61. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  62. Morgan Stanley Issues 2015 'Vintage Values' Stock List

    Benzinga
  63. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  64. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  65. Bind Therapeutics

    IBD
  66. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  67. Bind Therapeutics Down After Losing Amgen Partnership

    IBD
  68. Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge ...

    Benzinga
  69. Morning Market Losers

    Benzinga
  70. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  71. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  72. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  73. UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

    Benzinga
  74. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  75. UPDATE: Morgan Stanley Reiterates On Amgen Following AMAGINE-1 ...

    Benzinga
  76. Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and ...

    GuruFocus
  77. Amgen

    IBD
  78. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  79. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  80. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  81. Stocks End Six-Day Win Streak As Techs Sell Off

    IBD
  82. Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles

    IBD
  83. #PreMarket Primer: Wednesday, April 23: Data From China Takes ...

    Benzinga
  84. AMGEN

    IBD
  85. Gilead Soars As Hep C Drug Shatters Views; Amgen Misses

    IBD
  86. Rallying Ahead of Earnings

    FoxBusiness
  87. Nasdaq, S&P 500 On Track For Sixth Straight Gain

    IBD
  88. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  89. Stocks Power Out Early Gains; Allergan Leads Drug-Maker Surge

    IBD
  90. Earnings Scheduled For April 22, 2014

    Benzinga
  91. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  92. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  93. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  94. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable ...

    Benzinga
  95. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  96. Cholesterol drug meets goal

    IBD
  97. Trial Results Lift Drug Sector

    IBD
  98. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  99. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  100. Gilead Adds To Biotech Woes

    IBD
Trading Center